Good combination therapy, alpha-blocker and imidafenacin, for Nocturia of Benign Prostatic Hyperplasia with OAB in Osaka-Hokuriku study group

Trial Profile

Good combination therapy, alpha-blocker and imidafenacin, for Nocturia of Benign Prostatic Hyperplasia with OAB in Osaka-Hokuriku study group

Completed
Phase of Trial: Phase IV

Latest Information Update: 01 May 2015

At a glance

  • Drugs Imidafenacin (Primary) ; Alpha 1 adrenergic receptor antagonists; Alpha 1a adrenergic-receptor antagonists
  • Indications Benign prostatic hyperplasia; Nocturia; Overactive bladder
  • Focus Therapeutic Use
  • Acronyms GOOD-NIGHT
  • Most Recent Events

    • 24 May 2012 Results presented at the 107th Annual Meeting of the American Urological Association.
    • 28 Feb 2012 Results presented at the 27th Congress of the European Association of Urology.
    • 19 Sep 2011 Status changed from active, no longer recruiting to completed as reported by University Hospital Medical Information Network - Japan.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top